Oligomannate is a potential therapy for Alzheimer’s disease being developed by Shanghai Green Valley Pharmaceuticals. The treatment was given conditional approval in China, pending further safety and efficacy studies. A pivotal trial is planned for 2020 in the U.S., EU and elsewhere that might lead to requests for approval in those countries.
What is Alzheimer’s disease?
Alzheimer’s disease is a progressive neurodegenerative disorder that is the most common cause of dementia.
Healthy brains are made up of nerve cells that connect regions of the brain and send information to and from the brain and the rest of the body. In Alzheimer’s disease, there are misfolded proteins called beta-amyloid. Instead of being cleared, as in normal brains, these proteins build up and clump together, forming plaques.
How does oligomannate work?
Last updated: Nov. 6, 2019